Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Arrowhead Pharmaceuticals, Inc. - Common Stock (NQ:ARWR)

29.31 +0.64 (+2.23%)
Streaming Delayed Price Updated: 3:24 PM EDT, Sep 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Arrowhead Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
Why Shares in Arrowhead Pharmaceuticals Surged on News of a Novartis Deal
The announcement of a landmark deal with a pharmaceutical giant validates Arrowhead's technology. 
Via The Motley Fool
Air Lease, Ionis Pharmaceuticals, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday
 
Via Benzinga
Arrowhead Stock Rockets 11% Today – Retail Says $200M Upfront Payment From Novartis Collaboration Is ‘Hell Of A Deal’
Via Stocktwits
Arrowhead Pharma Jumps After Inking A Deal Worth Up To $2.2 Billion
Arrowhead Pharmaceuticals and Novartis inked a licensing deal Tuesday for an experimental Parkinson's drug. 
Via Investor's Business Daily
Earnings Scheduled For August 7, 2025
 
Via Benzinga
Arrowhead Pharma Expects Sarepta Therapeutics To Continue Meeting Financial Obligations: Retail Cheers The Announcement
Via Stocktwits
Earnings Scheduled For May 12, 2025
 
Via Benzinga
This Analyst Says Sarepta Lost Credibility By Exiting Arrowhead At A Loss, But Retail Sees Stock Hitting $30 By Next Week
H.C. Wainwright has a ‘Sell’ rating on the stock and a $5 price target, representing a near 75% downside from the stock’s closing price on Wednesday. 
Via Stocktwits
Sarepta Sells Arrowhead Stake To Stretch Its Cash Runway; And One Stock Dives
Arrowhead Pharmaceuticals stock tumbled Thursday after Sarepta Therapeutics liquified its entire stake in the company. 
Via Investor's Business Daily
Topics Death
Sarepta Keeps Retail Traders Bullish As Stock Surges On $100M Milestone Payment To Arrowhead In Genetic Disorder Trial
Sarepta sold part of its Arrowhead stake to help fund the milestone payment, while also outlining plans to release early data from two genetic therapy programs in the second half of 2025. 
Via Stocktwits
Arrowhead (ARWR) Q3 2025 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Arrowhead (ARWR) Q3 Revenue Drops 41%
Via The Motley Fool
Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) Reports Mixed Q3 2025 Results with Revenue Beat but Wider-Than-Expected Loss
Arrowhead Pharmaceuticals reported mixed Q3 2025 results, beating revenue estimates but missing on EPS. Stock fell 5.3% as higher R&D costs widened losses. Key pipeline updates include plozasiran NDA... 
Via Chartmill
Sarepta Therapeutics Surges Over 40% In Tuesday Pre-Market: What's Going On?
Stock of Sarepta Therapeutics Inc. (NASDAQ: SRPT) surged 38.89% in Tuesday pre-market following the U.S. Food and Drug Administration's (FDA) recommendation to lift the voluntary hold on Elevidys,... 
Via Benzinga
FDA Probes Death Of 8-Year-Old Who Received Sarepta's Elevidys
FDA probes Elevidys after an 8-year-old's death in Brazil; Sarepta and Roche say the death was unrelated to gene therapy treatment. 
Via Benzinga
Sarepta Gets Thumbs Down From Regulators Regarding Elevidys Gene Therapy
Sarepta and Roche face a regulatory setback as the EMA's CHMP issues a negative opinion on Elevidys for Duchenne muscular dystrophy patients. 
Via Benzinga
Sarepta Therapeutics' Brutal Week Continues With Bad News Out Of Europe
Shares are down another double-digit percentage after bad news continued piling on for gene therapy Elevidys. 
Via Investor's Business Daily
Topics Death
GE Vernova Posts Better-Than-Expected Earnings, Joins Thermo Fisher Scientific, Lennox International, General Dynamics And Other Big Stocks Moving Higher On Wednesday
 
Via Benzinga
Sarepta Reverses Course, Pauses Elevidys Shipments Amid FDA Safety Review
Sarepta pauses U.S. Elevidys shipments to complete FDA-requested safety label updates, aiming to resume distribution in the fourth quarter. 
Via Benzinga
Jim Cramer: Arrowhead Pharmaceuticals Doesn't 'Have The Horses'
Arrowhead Pharmaceuticals, Snowflake, Dover and Fluor are each in focus on today's edition of "Mad Money Lightning Round." 
Via Benzinga
Archer Aviation Posts Narrower-Than-Expected Loss, Joins Microvast, Intuitive Machines And Other Big Stocks Moving Higher On Tuesday
 
Via Benzinga
Why Coinbase Global Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Which stocks are moving after the closing bell on Monday?
The US market regular session of Monday is over, let's have a look at the top gainers and losers in the after hours session today. 
Via Chartmill
Insights Ahead: Arrowhead Pharma's Quarterly Earnings
 
Via Benzinga
Arrowhead Pharmaceuticals Stock Falls After Early-Stage Data From RNA-Based Therapeutic For Kidney Diseases
Arrowhead's ARO-C3 cut C3 levels by up to 89% and proteinuria by 41% in a Phase 1/2 trial. Additional results will be presented at a 2025 medical meeting. 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
Earnings Scheduled For February 10, 2025
 
Via Benzinga
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.
Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up. 
Via Investor's Business Daily
Topics Artificial Intelligence Government
Archer Aviation, Hims & Hers Health And Urban Outfitters Are Among Top 8 Mid-Cap Gainers Last Week (Nov 25-Nov 29): Are The Others In Your Portfolio?
8 mid-cap stocks saw impressive gains last week. Archer, Scholar Rock, Arrowhead, Iris Energy, Hims & Hers, SoundHound, Joby Aviation, and Urban Outfitters all performed well. 
Via Benzinga
Rivian Automotive, Rocket Lab And Moderna Are Among Top 10 Large-Cap Gainers Last Week (Nov 25-Nov 29): Are The Others In Your Portfolio?
Top performers last week: RIVN, RKLB, SRPT, EXAS, ESTC, ULTA, MRNA, RL, CPRT, SNAP. Any in your portfolio? Citigroup raises price target on ULTA and SNAP. 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.